Revenue and GTM
Consumer health and safety signal monitor: CRISPR tech selectively shreds cancer cells, including "undruggable" cancers
Revenue: $250K-$2M ARR potential if the wedge proves budget urgency and becomes a recurring workflow.
GTM: Start with manual concierge output, direct outreach, and community proof before paid acquisition.
Execution: Execution is moderate; the main constraint is staying narrow enough for a first proof loop.
Technology operations signal monitor: Show HN: Kage – Shadow any website to a single binary for offline viewing
Revenue: $250K-$2M ARR potential if the wedge proves budget urgency and becomes a recurring workflow.
GTM: Start with manual concierge output, direct outreach, and community proof before paid acquisition.
Execution: Execution is moderate; the main constraint is staying narrow enough for a first proof loop.
Which founder should pick which?
Consumer health and safety signal monitor: CRISPR tech selectively shreds cancer cells, including "undruggable" cancers best fits the Research Strategist (63/100 fit), while Technology operations signal monitor: Show HN: Kage – Shadow any website to a single binary for offline viewing best fits the Operator Builder (63/100 fit). Choose by the founder advantage you can actually bring to the first validation sprint.
- Consumer health and safety signal monitor: CRISPR tech selectively shreds cancer cells, including "undruggable" cancers: You spot uneven information quality, package evidence, and sell clarity to teams that make repeated decisions.
- Technology operations signal monitor: Show HN: Kage – Shadow any website to a single binary for offline viewing: You win by improving a painful workflow you understand, then turning the repeatable part into software.